title: Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.
abstract: BACKGROUND
  The ADAGIO study included a large cohort of patients with early PD (baseline total-UPDRS = 20) who were initially randomized to rasagiline and placebo, thereby allowing analyses of symptomatic efficacy.
  
  
  METHODS
  Post-hoc analyses comparing the efficacy of rasagiline 1 mg/day (n = 288) versus placebo (n = 588) on key symptoms at 36 weeks, and on total-UPDRS scores over 72 weeks (completer population: rasagiline 1 mg/day n = 221, placebo n = 392) were performed.
  
  
  RESULTS
  Treatment with rasagiline resulted in significantly better tremor, bradykinesia, rigidity and postural-instability-gait-difficulty scores at week 36 versus placebo. Whereas the placebo group experienced progressive deterioration from baseline (2.6 UPDRS points at week 36), patients in the rasagiline group were maintained at baseline values at week 60 (UPDRS-change of 0.3 points). At week 72, patients who had received continuous monotherapy with rasagiline experienced a worsening of only 1.6 points.
  
  
  CONCLUSIONS
  Treatment with rasagiline maintained motor function to baseline values for at least a year with significant benefits observed in all key PD motor symptoms.
authors.affiliation: Parkinson's Disease Center and Movement Disorders Clinic, Dept of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: josephj@bcm.tmc.edu.
authors.forename: Joseph
authors.initials: J
authors.lastname: Jankovic
authors.affiliation: Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel.
authors.forename: Elijahu
authors.initials: E
authors.lastname: Berkovich
authors.affiliation: Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel.
authors.forename: Eli
authors.initials: E
authors.lastname: Eyal
authors.affiliation: Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Catalonia, Spain.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Tolosa
mesh_terms: D015331:Cohort Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D007189:Indans; D018696:Neuroprotective Agents; C031967:rasagiline
keywords: Monotherapy; Parkinson's disease; Rasagiline